Animal health has been picking up speed in the last few years due to increasing awareness regarding prevalence of food-borne and zoonotic diseases. As such, the players involved in animal health market are keen to produce advanced pharmaceuticals and vaccines. By type of animal, the animal health market spans production animal (swine, poultry, cattle, goats & sheep, and fish) and companion animal (cats, dogs, horses, and others). By type of product, it’s vaccines (DNA vaccines, live attenuated vaccines, recombinant vaccines, inactivated vaccines, and others), pharmaceuticals (parasiticides, anti-infectives, anti-inflammatory, analgesics, and others), feed additives (medicinal and nutritional), diagnostics (consumables and instruments).
Besides, growing occurrences of parasitic infection in livestock and pet animals has gone ahead with creation of lucrative opportunities for animal parasiticides market. By type of product, the animal parasiticides market spans endectocides, endoparasiticides, and ectoparasiticides. Coming to developments, Bayer Animal Healthcare, in July 2018, did enter into a licensed agreement with “Mitsui Chemicals Agro” for expanding the parasiticides’ portfolio for the companion animals.
Canine stem cell therapy comes across as one of the disease-modifying therapies to treat degenerative disorders like arthritis of shoulders, elbows, hips, and likewise. By type, it’s allogenic stem cells and autologous stem cells. Application-wise, it’s research and treatment. End-user-wise, it’s veterinary research institutes, veterinary clinics, and veterinary hospitals.
Coming to ailments on the human part, fluoroscopy and C-Arms market is witnessing tremendous growth. By type of product, it’s, as the name suggests, fluoroscopy devices and C-Arms. Application-wise, it’s discography, angiography, and image-guided biopsy. Growing incidences of cardiovascular ailments are responsible for the growth of fluoroscopy and C-Arms market.
Cell-free protein expression implies production of recombinant proteins by employing cell lysates. Bacterial or eukaryotic cells’ components are used for producing cell lysates. At present, cell-free protein expression systems are based on rabbit reticulocytes, human cell lines, wheat germs, and insect cells. As such, by product, they could be categorized into E. Coli lysate, insect cell lysate, human cell lysate, wheat germ lysate, rabbit reticulocyte lysate, and others. Application-wise, they are high throughput production, enzyme engineering, protein labelling, protein-protein interaction, and others.
Kidney dialysis equipment market, by type of dialysis equipment, spans peritoneal dialysis equipment, peritoneal dialysis equipment, and hemodialysis equipment. Regarding developments, Baxter International Inc., in January 2019, received approval from the US FDA for clinical trial pertaining to on-demand peritoneal dialysis solution generation system. As such, home care could be exercised well. Also, Fresenious Medical Care, in the year 2017, started its novel production facility all across Malaysia to catalyze manufacturing advanced continuous ambulatory peritoneal dialysis materials.
Coming to uveitis, The College of Optometrists has stated that 12 per 100K people suffer from anterior uveitis every single year. Also, medical records from California communities state that uveitis results in nearly 30K new-fangled cases of blindness annually, which contributes to 10% of the blind cases on the whole.
Crohn’s disease diagnostics and therapeutics market, by diagnostics, spans capsule endoscopy, MRI, computerized tomography, flexible sigmoidoscopy, colonoscopy, decal test, and blood test. By mode of treatment, it’s medication (analgesics and antipyretics, immunosuppressants, and anti-inflammatory agents) and surgery. Research states that westernization regarding lifestyles is the basic factor contributing to the occurrence of Crohn’s disease. The US alone has over 75K people staying with Crohn’s disease.
The global MicroRNA market, by product, spans instruments and Kits & Reagents. Application-wise, it’s detection & quantification, isolation & purification, disease diagnostics, and many others. End-user-wise, it’s biotech & pharma companies, research & academic institutes, healthcare facilities, and likewise. MicroRNA is being increasingly used in the form of modulator for drug resistance, biomarkers for pathogens, and also for drugs for medical intervention. Regarding developments, Novartis, in November 2019, did announce acquisition of “The Medicines Company” for US$ 9.7 Bn, so as to add the potentially first-in-class miRNA and siRNA inhibitor for altering treatment of elevated LDL-C (low-density lipoprotein cholesterol) in the high-risk patients.
Arbovirus testing market, by type of test, spans RT-PCR based tests, ELISA-based tests, and others. End-user-wise, it’s hospitals, diagnostic laboratories, research centers, and many others. The factors basically contributing to the growth of arbovirus testing market include the growing occurrences of arbovirus across the globe, and not to forget, emerging rapid serology tests. Arboviral infectious diseases are inclusive of chikungunya, dengue, yellow fever, St. Louis encephalitis, California encephalitis, Powassan, Eastern Equine encephalitis, Zika, and West Nile.
Persistence Market Research (PMR) has profiled the key players in two healthcare arms (human and animal) as follows:
- Varex Imaging Corporation
- Carestream Health
- CellFree Sciences Co. Ltd.
- Cube Biotech GmbH
- Baxter International Inc.
- Fresenius Medical Care
- Santen Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals
- Celgene Corporation
- Janssen Biotech Inc.
- GeneCopoeia, Inc.
- NanoString Technologies, Inc.
- Abbott Laboratories
- NovaTec Immundiagnostics GmbH
- Merck Animal Health
- Zeotis
- Ceva Sante Animale
- Elanco
- Bayer Animal Healthcare
- Medrego
- VetStem Biopharma
- Magellan Stem Cells
Wanda Rich has been the Editor-in-Chief of Global Banking & Finance Review since 2011, playing a pivotal role in shaping the publication’s content and direction. Under her leadership, the magazine has expanded its global reach and established itself as a trusted source of information and analysis across various financial sectors. She is known for conducting exclusive interviews with industry leaders and oversees the Global Banking & Finance Awards, which recognize innovation and leadership in finance. In addition to Global Banking & Finance Review, Wanda also serves as editor for numerous other platforms, including Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune.